Synonyms: RC18 | Tai'ai®
telitacicept is an approved drug (China (2021))
Compound class:
Peptide
Comment: Telitacicept (RC18) is a recombinant fusion protein that combines the ligand-binding domain of the TACI receptor and the Fc component of human IgG. It was designed to inhibit the signalling of B cell BAFF and APRIL as a mechanism to treat B cell-mediated autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) [2-5].
|
Classification | |
Compound class | Peptide |
Approved drug? | Yes (China (2021)) |
International Nonproprietary Names | |
INN number | INN |
10932 | telitacicept |
Synonyms |
RC18 | Tai'ai® |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 895 |
Other databases | |
GtoPdb PubChem SID | 461663383 |
Search PubMed clinical trials | telitacicept |
Search PubMed titles | telitacicept |
Search PubMed titles/abstracts | telitacicept |